 |
|
Literature review highlights options for self-management of asthma exacerbations
July 05, 2006An extensive literature review undertaken by the Woolcock Institute of Medical Research has examined the pharmacological strategies for self-management of asthma exacerbations in adults, including those using inhaled corticosteroid/long-acting â2-agonist (ICS/LABA) therapy.
The review provides evidence-based recommendations on the best way to use oral corticosteroids (OCS) to treat severe exacerbations and questions whether studies support the common practice of doubling inhaled corticosteroids (ICS) doses as a form of treatment. It also looks at whether increasing ICS to high doses is an alternative to OCS, as well as the effects of increasing the dose of combination therapy during exacerbations.
Use of inhaled ICS/LABA for maintenance and relief, and the effectiveness of short- acting â2-agonist (SABAs) in the management of exacerbations have also been addressed.
Dr Helen Reddel of the Woolcock Institute and Dr David Barnes from Royal Prince Alfred Hospital, authors of the narrative review which is published in the latest issue of European Respiratory Journal, said the project was undertaken in a bid to help clinicians determine the specific therapeutic instructions which should be included in written asthma action plans.
Dr Reddel explains most of the advice in current international guidelines about how to manage exacerbations was published prior to the introduction of combination therapy.
"However recent years have seen an increase in the proportion of patients being prescribed combination inhaled corticosteroid/long-acting â2-agonist therapy in one inhaler device for the management of persistent asthma," she said.
"The review recognises the importance of written action plans as a beneficial part of an integrated program to substantially improve health outcomes for people with asthma. Our aim was to determine what recommendations should be included in these plans and to make sure they encompass patients taking combination therapy," she said.
A Medline search was used to review relevant papers covering the period 1990-2004. Key findings include:
- Oral corticosteroids are well established in clinical practice and clinical trials for the treatment of severe exacerbations, including during treatment with combination therapy. Evidence supports 7-10 days treatment with no need to taper except to reduce side effects.
- Three studies have shown that doubling the dose of ICS is not effective for treatment of exacerbations.
- Several studies have shown benefit from high dose ICS (2400-4000ìg beclomethasone equivalent) for 1-2 weeks. This may be achieved by adding a high-dose ICS inhaler to maintenance ICS or ICS/LABA therapy.
- There is inconclusive evidence about acutely increasing the dose of maintenance budesonide/formoterol after onset of an exacerbation, and no studies of this approach with fluticasone/salmeterol.
- For patients taking maintenance budesonide/formoterol, use of the same medication as-needed, including when asthma is worsening, reduces exacerbations.
- Short-acting â2-agonists are still effective in producing bronchodilation during combination therapy; however a higher dose may be required. Patients who are taking combination therapy should be reminded that they may use
short-acting â2-agonists for relief of symptoms.
Dr Reddel points outs there is a need for further studies to clarify remaining issues about self-management of asthma exacerbations, particularly with regard to side-effects of treatment and patient acceptability.
Research Australia
Dr Helen Reddel of the Woolcock Institute and Dr David Barnes from Royal Prince Alfred Hospital, authors of the narrative review which is published in the latest issue of European Respiratory Journal, said the project was undertaken in a bid to help clinicians determine the specific therapeutic instructions which should be included in written asthma action plans.
Dr Reddel explains most of the advice in current international guidelines about how to manage exacerbations was published prior to the introduction of combination therapy.
"However recent years have seen an increase in the proportion of patients being prescribed combination inhaled corticosteroid/long-acting â2-agonist therapy in one inhaler device for the management of persistent asthma," she said.
"The review recognises the importance of written action plans as a beneficial part of an integrated program to substantially improve health outcomes for people with asthma. Our aim was to determine what recommendations should be included in these plans and to make sure they encompass patients taking combination therapy," she said.
A Medline search was used to review relevant papers covering the period 1990-2004. Key findings include:
- Oral corticosteroids are well established in clinical practice and clinical trials for the treatment of severe exacerbations, including during treatment with combination therapy. Evidence supports 7-10 days treatment with no need to taper except to reduce side effects.
- Three studies have shown that doubling the dose of ICS is not effective for treatment of exacerbations.
- Several studies have shown benefit from high dose ICS (2400-4000ìg beclomethasone equivalent) for 1-2 weeks. This may be achieved by adding a high-dose ICS inhaler to maintenance ICS or ICS/LABA therapy.
- There is inconclusive evidence about acutely increasing the dose of maintenance budesonide/formoterol after onset of an exacerbation, and no studies of this approach with fluticasone/salmeterol.
- For patients taking maintenance budesonide/formoterol, use of the same medication as-needed, including when asthma is worsening, reduces exacerbations.
- Short-acting â2-agonists are still effective in producing bronchodilation during combination therapy; however a higher dose may be required. Patients who are taking combination therapy should be reminded that they may use
short-acting â2-agonists for relief of symptoms.
Dr Reddel points outs there is a need for further studies to clarify remaining issues about self-management of asthma exacerbations, particularly with regard to side-effects of treatment and patient acceptability.
Research Australia
Exacerbations Current Events and Exacerbations News RSSNew clinical guidelines for exacerbations in cystic fibrosis
The American Thoracic Society has released new clinical guidelines for the treatment of exacerbations in cystic fibrosis based on a review of the literature on current clinical practices.
New vaccine shows promise for COPD patients at risk for pneumonia
A new vaccine against pneumonia may offer better protection from chronic obstructive pulmonary disease (COPD) patients than the currently accepted vaccine, according to recent research that will be published in the September 15 issue of the American Journal of the Respiratory and Critical Care Journal, a publication of the American Thoracic Society.
New asthma predictors needed to determine future risk in certain patients
Screening tests used to predict asthma activity in patients may have little tracking success when applied to people with persistent disease who are adhering to their health care regimens, UT Southwestern Medical Center physician report.
NIAID media availability: Still searching for predictors of asthma attacks
A new study of persistent asthma in inner-city adolescents and young adults finds that an extensive set of clinical tests cannot successfully predict the future risk of asthma attacks in participants who both receive care based on current guidelines and adhere to treatment recommendations.
LSUHSC shows for first time infant inhalation of ultrafine air pollution linked to adult lung disease
Stephania Cormier, Ph.D., Associate Professor of Pharmacology at LSU Health Sciences Center New Orleans, has shown for the first time that early exposure to environmentally persistent free radicals (present in airborne ultrafine particulate matter) affects long-term lung function.
ATS, ERS jointly issue asthma assessment guidelines
The American Thoracic Society and the European Respiratory Society have released official standards for clinical trials and practice with respect to the assessment of asthma.
Could hormones explain gender differences in neurological disease?
Neurological diseases including Parkinson's, Tourette's, attention deficit hyperactivity disorder (ADHD), Alzheimer's, and schizophrenia are all associated with alterations in dopamine-driven function involving the dopamine transporter (DAT).
Obesity Does Not Worsen Asthma, But May Effect Response to Medications
Being overweight or obese does not make asthma worse in patients with mild and moderate forms of the disease, according to a study by National Jewish Health researchers, although it may reduce the response to medications.
Self-treatment results in lower overall health care costs for COPD sufferers
Individuals suffering from chronic obstructive pulmonary disorder (COPD) can experience significant savings in healthcare costs by employing a self-treatment program with the judicious use of medications.
Cigarette smoke may alter immune response in COPD exacerbations
Smoking cigarettes is not only the principle cause of chronic obstructive pulmonary disease (COPD), but it may change the body's immune responses to bacteria that commonly cause exacerbations of the disease, according to new research in a mouse model.
More Exacerbations Current Events and Exacerbations News Articles
 |
???????? ?????????? (Spring Exacerbations) Billy's Band (Primary Contributor) |
 |
Acute Exacerbations in COPD by M. Cazzola (Editor), S. Sethi (Editor), F. Blasi (Editor), A. Anzueto (Editor) The pronounced variability in the incidence and severity of chronic respiratory diseases such as asthma and COPD, makes effective treatment more difficult, and the social and economic costs of these diseases all the greater. Acute exacerbations are multi-factorial in origin, and are known to be linked with a number of factors including allergens, atmospheric pollution and infectious agents. Effective treatment requires a similarly complex approach that addresses each of the component causes. This text brings together current knowledge of the epidemiology and pathophysiology of these episodes, and the latest experimental models by which researchers are seeking to improve our understanding of their incidence and progression. The book concludes with a review of the latest ideas on therapy... |
|
|
29 ????? (March, 29th ) (Instrumental) Billy's Band (Primary Contributor) |
 |
Exacerbation Post Scriptum (Primary Contributor) |
|
Exacerbation of psychosis by misinterpretation of physical symptoms. (Case Report).: An article from: Southern Medical Journal by Roy R. Reeves (Author), Rafael A. Torres (Author) This digital document is an article from Southern Medical Journal, published by Southern Medical Association on July 1, 2003. The length of the article is 1974 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Exacerbation of psychosis by misinterpretation of physical symptoms. (Case Report). Author: Roy R. Reeves Publication: Southern Medical Journal (Refereed) Date: July 1, 2003 Publisher: Southern Medical Association Volume: 96 Issue: 7 Page: 702(3) Distributed by Thomson... | |
|
|
???????? ?????????? (Spring Exacerbations) Billy's Band (Primary Contributor) |
|
Low vitamin D levels in kids tied to asthma exacerbations.(Across Specialties): An article from: Skin & Allergy News by Mitchel L. Zoler (Author) This digital document is an article from Skin & Allergy News, published by International Medical News Group on August 1, 2008. The length of the article is 610 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: Low vitamin D levels in kids tied to asthma exacerbations.(Across Specialties) Author: Mitchel L. Zoler Publication: Skin & Allergy News (Magazine/Journal) Date: August 1, 2008 Publisher: International Medical News Group Volume: 39 Issue: 8 Page: 62(1) Distributed by Gale, a part of Cengage... | |
|
|
??????? - ??????? ???? (??????????)/ Kupchino-Capital of the World (Farewell) Billy's Band (Primary Contributor) |
 |
Mechanisms and Management of COPD Exacerbations by L. Allegra (Author), F. Blasi (Author) Chronic obstructive pulmonary disease (COPD) is an increasingly important health problem world-wide. Whereas most other leading diseases have shown a decline in the past decades, COPD morbidity and mortality is on a steady increase. Exacerbations are usually defined as an increase in cough, a change in the colour or quantity of sputum, and a worsening dyspnea. The role of bacterial infections and the efficacy of antimicrobial therapy in acute exacerbations of chronic bronchitis (AECD) is still controversial. Exacerbations of chronic bronchitis are a common occurrence in clinical practice and are a leading cause of antibiotic prescription among respiratory infections. It is still uncertain whether each new exacerbation may deteriorate the natural history of chronic bronchitis. Undoubtedly,... |
|
|
??? ?? ????? (Lay Down on the Ground) Billy's Band (Primary Contributor) |
| © 2009 BrightSurf.com |